

95. The Adamantane Rearrangement of *syn*- and *anti*-Tricyclo[4.2.1.1^{2,5}]decane

Part II¹⁾

Rearrangements Initiated by Regioselective Formation of Carbocations at C(3) and C(9)

by Marco Brossi²⁾ and Camille Ganter*

Laboratorium für Organische Chemie der Eidgenössischen Technischen Hochschule, ETH-Zentrum,
Universitätstrasse 16, CH-8092 Zürich

(11.II.88)

The *endo*- and *exo*-alcohols **5–12** of *syn*- (**1**) and *anti*-tricyclo[4.2.1.1^{2,5}]decane (**2**) were treated with BF₃/Et₃SiH (ionic hydrogenation) in order to study the behaviour of the corresponding regioselectively generated carbocations at C(3) (**a** (*syn*), **b** (*anti*)) and C(9) (**c** (*syn*), **d** (*anti*)). The *anti*-hydrocarbon **2** is practically the sole product obtained starting with the four 3-alcohols (via **a** → **b** from **5** and **6** (*syn*) and via **b** from **9** and **10** (*anti*)). The four 9-alcohols in each case yield a mixture of 2-*endo*, 3-*endo*- (**3**) and 2-*exo*, 3-*exo*-trimethylene-8,9,10-trinorbornane (**4**) (via **c** → **e** from **7** and **8** (*syn*) and via **d** → **f** from **11** and **12** (*anti*)), but no hydrocarbon **2**, i.e. none of the 1,3-H shifts **c** → **a** and **d** → **b** is involved.

In the presence of AlBr₃ in CS₂, *syn*-tricyclo[4.2.1.1^{2,5}]decane³⁾ (**1**) isomerizes exclusively to *anti*-tricyclo[4.2.1.1^{2,5}]decane³⁾ (**2**), whereby hydride abstraction occurs at C(3) (→ carbocation **a**). Neither 2-*endo*, 3-*endo*- (**3**) nor 2-*exo*, 3-*exo*-trimethylene-8,9,10-trinorbornane (**4**) is observed. The *anti*-isomer **2** rearranges to **4**, most probably as the result of hydride abstraction at C(9) (→ carbocation **d**) [1].

In order to obtain more detailed information about the adamantane rearrangement⁴⁾ of both **1** and **2**, we applied the ionic hydrogenation method⁵⁾, by which we were able to generate regioselectively each of the four possible secondary carbocations at C(3) and C(9): **a** and **c** of the *syn*-isomer **1** as well as **b** and **d** of the *anti*-isomer **2**. As substrates for our studies we used **5–12**, the *endo*- and *exo*-alcohols³⁾ at C(3) and C(9). The heterolyses

¹⁾ For Part I, see [1].

²⁾ Present address: Ciba-Geigy AG, CH-4002 Basel.

³⁾ The configurational prefixes *syn* and *anti* are used for compounds **1**, **2**, **5–12**, **16–26**, and **28–31** with the two methylene bridges (CH₂(9) and CH₂(10)) on the same and opposite side, respectively, of the plane C(1)–C(2)–C(5)–C(6). In these compounds, an *exo* substituent lies in a plane parallel to the reference plane C(1)–C(2)–C(5)–C(6) and an *endo* substituent stands out from this parallel plane.

⁴⁾ 'Adamantaneland': a set of 19 isomeric saturated, tricyclic C₁₀H₁₆ hydrocarbons, which contain neither a three- nor a four-membered ring, and no alkyl group [2–4]. 'Adamantane rearrangement': rearrangement of any one of the 18 adamantane isomers to any other member of the *adamantaneland* via carbocation intermediates, eventually resulting in the formation of the thermodynamically most stable product, the adamantane [2–4].

⁵⁾ See the review [5] and ref. cit. therein.

of the C—O bonds were effected at room temperature by gaseous BF_3 , and the primarily formed and/or the rearranged carbocations were trapped by Et_3SiH . The results are summarized in the *Table*.




Table. Treatment of the Alcohols 5–12 with $\text{BF}_3/\text{Et}_3\text{SiH}$

Run	Reactant	Reaction time [min]	Composition [%] ^{a)}					
			Reactant	2	3	13	4	14
1	5	5–10	5–10	80–85	5			
2	6	5–10	30–35	55–60				
3	6	60	10	85	< 5			
4	7	5–10			50–55	10	30–35	
5	8	5–10			20–25	5	40–45	b)
6	9	5–10		95	5			
7	10	5–10	85–90	5				
8	10	60	70	15	< 5			
9	11	5–10			40–45		40	15–20 ^{c)}
10	12	5–10			35–40		35–40	20–25

^{a)} Average of ≥ 3 experiments. Combined yield of products: $\geq 90\%$; the compositions were determined by cap. GLC (*SE 52*); compounds in $< 5\%$ are not listed.

^{b)} In addition, 15–25% of **15**⁸⁾.

^{c)} In addition, 5% of unidentified products.

The following features were observed and the following conclusions could be drawn: a) of a given pair of diastereoisomers, especially in the case of the 3-alcohols, the 'exo'-alcohol is remarkably more reactive than the sterically more hindered 'endo'-alcohol (**5** > **6**, **9** > **10**). However, this difference in reactivity has no influence on the ratio of the products formed.

b) Carbocations of C(9) at the CH_2 bridges (**c** and **d**) are generated more rapidly (total conversion of the reactants is achieved already after 5–10 min, *Runs 4, 5, 9*, and *10*) than those of C(3) of the CH_2CH_2 bridges (**a** and **b**, *Runs 1–3* and *6–8*).


c) All four 3-alcohols (**5** and **6** ('syn'), **9** and **10** ('anti')) yield almost exclusively the 'anti'-hydrocarbon **2** (*Runs 1–3* and *6–8*)⁶⁾. For **5** and **6**, this result can best be interpreted in terms of the intermediacy of the 'syn'-carbocation **a** which rearranges to the 'anti'-carbocation **b**; these species undergo a 1,3-H shift to **c** and **d**, respectively, only to very minor extents ($\leq 5\%$ of **3**; dotted arrows in *Scheme 1*). This result is consistent with the isomerization of **1** into **2** on treatment with AlBr_3 [*1*].

d) A completely different reaction course is followed starting from the 9-alcohols **7** and **8** ('syn'; *Runs 4* and *5*) as well as **11** and **12** ('anti'; *Runs 9* and *10*). No trace of 'anti'-hydrocarbon **2** could be detected, it suggests that none of the possible 1,3-H shifts **c** \rightarrow **a** and **d** \rightarrow **b** is operative. In each case, a mixture of 2-endo,3-endo- (**3**) and 2-exo,3-exo-trimethylene-8,9,10-trinorbornane (**4**) is obtained⁷⁾. In addition, depending on the C-skeleton of the reactants ('syn' or 'anti'), the 1',2'-olefin **13** (2-endo,3-endo; *Runs 4* and

⁶⁾ In very small amounts ($\leq 5\%$), 2-endo,3-endo-trimethylene-8,9,10-trinorbornane (**3**) is formed as the only further product.


⁷⁾ This result is in sharp contrast to the AlBr_3 -catalyzed adamantane rearrangement of the 'anti'-hydrocarbon **2**, where only **4** (calc. $\Delta H_f^\circ = -16.77$ kcal/mol [*6*]), thermodynamically more stable than the isomers **3** (calc. $\Delta H_f^\circ = -12.31$ kcal/mol [*6*]; -14.36 kcal/mol [*7*]; exper. $\Delta H_f^\circ = -14.38$ kcal/mol [*8*]), is obtained.

⁸⁾ Further experiments have to be carried out to rationalize the appearance of 15–20% of 2-exo,3-exo-trimethylene-8,9,10-trinorborn-5-ene (**15**).



5) or **14** (2-*exo*,3-*exo*; *Runs* 9 and 10) is a by-product. They probably result from proton elimination at C(2') in the intermediate 1'-carbocations **e** and **f**, resp., which themselves originate from the 9-carbocations **c** ('*syn*') and **d** ('*anti*'), resp., by a 1,2-alkyl shift from C(1) to C(9). Independent of the alcoholic precursor (**7**, **8**, **11**, and **12**), both isomeric hydrocarbons **3** and **4**, are the main products. They are formed in nearly equal ratio (*Runs* 4 and 5⁸), 9 and 10) in all experiments. This indicates that their formation proceeds through common intermediates. Further studies, mainly with D-labelled reactants and Et₃SiD as trapping reagent are planned, hoping to gain more information about the involved reaction pathways.

Reactants and Products. – *Syntheses and Structure Assignments.* The following reactants and products have already been described earlier: **1** [9–12], **2** [9–11] [13], **3**



[14–17]⁹), **4** [13–17]⁹), **5** [10] [11]¹⁰), **8** [9]⁹), **9** [10] [11] [13]¹⁰), **12** [9]¹⁰), **13** [14–17]¹¹), **14** [14–17]¹²), **15** [14–17]¹³).

The novel alcohols **6**, **7**, **10**, and **11** were synthesized according to *Scheme 2*. A separable mixture of the unsaturated ketones **16** and **17** can be prepared according to *Schmid* [25].

Cycloaddition of the allylic cation generated from 5-chloro-1-morpholinocyclopentene to cyclopentadiene followed by base-catalyzed hydrolysis of the intermediate immonium salts yielded **16/17** in the ratio of 88:12. Recently, *Zimmerman* and *Linder* [26] described a new approach to the *anti*-isomer **17**: Triethylamine-catalyzed condensation of 2-chlorocyclopentanone with cyclopentadiene in MeOH, apparently, gave **17** in 15% yield as the sole product. However, carefully applying *Zimmerman*'s procedure, we obtained again a mixture **16/17** in the same ratio¹⁴) as *Schmid* [25].

Starting from the '*syn*'-ketone **16**, the 9-'*exo*'-alcohol **7** was prepared by two different routes. Reduction with Na in toluene yielded 70.5% of the unsaturated '*exo*'-alcohol **18**¹⁵) and 17.5% of the '*endo*'-alcohol **20**¹⁵). The former was transformed to the desired compound **7**¹⁵) by catalytic hydrogenation. Na-Reduction of the saturated ketone **23** [9] gave only 44.5% of **7**; in addition, 50.5% of the '*endo*'-alcohol **8** were isolated. The latter can easily be obtained as sole product from **16** via **20**.

Analogous was the preparation of the '*anti*'-9-'*exo*'-alcohol **11**¹⁵). Treatment of the unsaturated ketone **17** with Na in toluene led to 54% of the '*exo*'-alcohol **24**¹⁵), 9% of the corresponding '*endo*'-isomer **26** [27] [28], and 26% of the tetracyclic alcohol **27**. Subsequent catalytic hydrogenation of **24** yielded **11**. Reduction of the saturated ketone **29** [9] [13] [26] with Na gave 77% of **11** and 4% of the '*endo*'-isomer **12**.

The '*syn*'-3-'*endo*'-alcohol **6** was prepared by LiAlH₄ reduction of the corresponding ketone **30** [10] [11] and the '*anti*'-3-'*endo*'-alcohol **10** from ketone **31** [10] [11] [13].

Financial support by the *Swiss National Science Foundation* and by *Ciba-Geigy AG*, Basel is gratefully acknowledged. We are indebted to the following persons in the analytical department for their help: Miss *B. Brandenberg*, Mr. *F. Fehr* (NMR), Mrs. *L. Golgowsky*, and Prof. *J. Seibl* (MS).

Experimental Part

General. See [28] [29].

Procedures for the Ionic Hydrogenations of the Alcohols 5–12 with BF₃/Et₃SiH. a) *Preparative Scale.* A soln. of 100 mg (0.66 mmol) of reactant in 20 ml of CH₂Cl₂ (filtered through basic Al₂O₃) was treated with 150 μl (0.94 mmol) of Et₃SiH. Under Ar and vigorous stirring gas BF₃ was bubbled through the soln. (two-necked round bottom flask, fitted with a strong balloon and a septum) for 10 s. The reactions were quenched by adding 1 ml of sat. Na₂CO₃ soln. The mixture was stirred for 5 min, the org. layer sucked off with a syringe, dried (MgSO₄) and filtered. By careful bulb-to-bulb distillation the solvent was removed and the products distilled. The percentage of the compositions were determined by cap. GLC (*Carlo Erba Fractovap 4160* or *G1* using a 20 m or 50 m × 0.32 mm *SE 52* glass capillary column). Separation and isolation of the products was performed by prep. GLC (5% *SE 30* on *Chromosorb W* (80/100 mesh) AW-DMCS).

⁹) See also *e.g.* [18].

¹⁰) See also *Exper. Part*.

¹¹) See also *e.g.* [19–21] and *Exper. Part*.

¹²) See also *e.g.* [19] [22] [23] and *Exper. Part*.

¹³) See also *e.g.* [24].

¹⁴) The isolated yields were 3.5% of **16** and 23.5% of **17**.

¹⁵) The alcohols **7**, **11**, **18**, **20**, and **24** were also characterized as their corresponding acetates **22**, **28**, **19**, **21**, and **25**.

b) *Analytical Scale*. In analogy to the above procedure, with *ca.* 1–5 mg of reactant and the addition of adamantane or decane as internal standard.

syn-Tricyclo[4.2.1.1^{2,5}]decan-3-exo-ol (5). IR: 3620*m*, 3480*w* (br.), 3035*w*, 2980*m*, 2935*s*, 2890*m*, 1479*w*, 1466*w*, 1453*w*, 1318*w*, 1287*w*, 1236*w*, 1214*w*, 1058*m*, 1054*w* (sh), 1021*m*, 988*m*, 956*w*, 941*w*, 938*w*, 899*w*, 882*w*. ¹H-NMR: 0.54 (*dtm*, $J_{gem} = 11.5$, $J(1,9-exo) = J(6,9-exo) = 2.5$, $w_{1/2} \approx 2$, $H_{exo-C(9)}$); 1.03 (*ddt*, $J_{gem} = 14$, $J(4-exo, 5) = 6$, $J(3-endo, 4-exo) = J(2,4-exo) = 2$, $J \approx 0.5$, $H_{exo-C(4)}$); 1.04 (*dt*, $J_{gem} = 11.5$, $J(2,10-exo) = J(5,10-exo) = 3$, $H_{exo-C(10)}$); 1.15–1.35 (*m*, $H_{exo-C(7)}$, $H_{exo-C(8)}$); 1.26 (*m*, $w_{1/2} \approx 5$, $exo-HO-C(3)$); 1.6–1.75 (*m*, $H_{endo-C(7)}$, $H_{endo-C(8)}$); 1.79 (*ddt*, $J_{gem} = 11.5$, $J(4-endo, 10-endo) = 3$, $J(2,10-endo) = J(5,10-endo) = 1.5$, $H_{endo-C(10)}$); 1.91 (*dm*, $J_{gem} = 11.5$, $w_{1/2} \approx 6$, $H_{endo-C(9)}$); 2.07 (*dm*, $J(1,2) = 10$, $w_{1/2} \approx 6$, among others $J(2,10-exo) = 3$, $J(2,4-exo) = 2$, $J(2,3-endo) < 0.5$, $H-C(2)$); 2.2–2.35 (*m*, $H-C(1)$, $H-C(5)$, $H-C(6)$); 2.3–2.4 (*m*, $H_{endo-C(4)}$); 4.44 (*dddd*, $J(3-endo, 4-endo) = 6.5$, $J(3-endo, 4-exo) = 2$, $J(3-endo, 10-endo) = 1.5$, $J(2,3-endo) < 0.5$, $H_{endo-C(3)}$). ¹³C-NMR: 25.87, 26.65, 26.88, 30.34 (4*t*, C(7), C(8), C(9), C(10)); 34.45 (*t*, C(4)); 34.36, 36.17, 37.14 (3*d*, C(1), C(5), C(6)); 42.09 (*d*, C(2)); 76.41 (*d*, C(3)). MS: 152 (3, M^+ , C₁₀H₁₆O), 134 (47), 121 (14), 119 (20), 109 (13), 108 (27), 107 (11), 106 (24), 105 (23), 95 (17), 93 (51), 92 (31), 91 (31), 83 (17), 81 (19), 80 (65), 79 (100), 78 (23), 77 (22), 70 (19), 68 (12), 67 (67), 66 (64), 65 (11), 57 (16), 55 (25), 54 (23), 53 (18), 41 (48), 39 (33), 29 (13), 27 (20).

syn-Tricyclo[4.2.1.1^{2,5}]decan-3-endo-ol (6). A soln. of 25 mg (0.17 mmol) of **30** in 10 ml of abs. Et₂O was treated under Ar with a small amount of LiAlH₄ for 2 h at r.t. Workup with sat. (NH₄)₂SO₄ soln., filtration through *Celite*, removal of the solvent and CC on 3 g of silica gel in pentane/Et₂O 3:1 yielded 17.5 mg (69%) of **6**. IR: 3630*m*, 3020*w*, 2980*w*, 2935*s*, 2885*m*, 1481*w*, 1462*w*, 1454*w* (sh), 1440*w*, 1348*w*, 1314*w*, 1298*w*, 1278*m*, 1204*w*, 1162*m*, 1118*s*, 1053*m*, 1038*m*, 997*w*, 925*w*. ¹H-NMR: 0.57 (*dt*, $J_{gem} = 12$, $J(2,10-exo) = J(5,10-exo) = 2.5$, $H_{exo-C(10)}$); 0.57 (*dt*, $J_{gem} = 11$, $J(1,9-exo) = J(6,9-exo) = 2.5$, $H_{exo-C(9)}$); 1.2–1.5 (*m*, $H_{exo-C(7)}$, $H_{exo-C(8)}$); 1.53 (*ddd*, $J_{gem} = 13.5$, $J(3-exo, 4-endo) = 5$, $J(4-endo, 5) = 3.5$, $H_{endo-C(4)}$); 1.60 (*ddt*, $J_{gem} = 12$, $J(4-endo, 10-endo) = 3.5$, $J(2,10-endo) = J(5,10-endo) = 1.75$, $H_{endo-C(10)}$); 1.65–1.8 (*m*, among others $J(7-endo, 8-endo) = 8$, $H_{endo-C(7)}$); 1.69 (*m*, $w_{1/2} \approx 4$, $endo-HO-C(3)$); 1.75 (*dm*, $J_{gem} = 11$, $w_{1/2} \approx 7$ each, among others $J(8-endo, 9-endo) = 3$, $H_{endo-C(9)}$); 1.88 (*ddd*, $J_{gem} = 14$, $J(3-exo, 4-exo) = 10$, $J(4-exo, 5) = 7$, $H_{exo-C(4)}$); 2.2–2.3 (*m*, among others $J(1,2) \approx 8$, $J(5,6) \approx 8$, $J(4-endo, 5) = 3.5$, $J(2,10-endo) = J(10-endo, 5) = 1.75$, $H-C(2)$, $H-C(5)$); 2.35–2.45 (*m*, among others $J(1,2) \approx 8$, $J(5,6) \approx 8$, $H-C(1)$, $H-C(6)$); 2.66 (*dddd*, $J_{gem} = 13$, $J(7-endo, 8-endo) = 8$, $J(7-exo, 8-endo) = 4.5$, $J(8-endo, 9-endo) = 3$, $H_{endo-C(8)}$); 4.18 (*dt*, $J(3-exo, 4-exo) = 10$, $J(3-exo, 4-endo) = 5$, $J(2,3-exo) = 5$, $H_{exo-C(3)}$). ¹³C-NMR: 25.83, 26.56, 26.78, 30.28 (4*t*, C(7), C(8), C(9), C(10)); 34.33 (*d*, C(6)); 34.39 (*t*, C(4)); 36.09, 37.07 (2*d*, C(1), C(5)); 41.99 (*d*, C(2)); 76.28 (*d*, C(3)). MS: 152 (3, M^+ , C₁₀H₁₆O), 134 (52), 121 (14), 119 (26), 109 (14), 108 (28), 107 (11), 106 (27), 105 (33), 95 (16), 93 (56), 92 (40), 91 (41), 83 (15), 81 (20), 80 (65), 79 (100), 78 (25), 77 (25), 70 (18), 69 (10), 68 (11), 67 (73), 66 (85), 65 (12), 57 (16), 55 (41), 54 (21), 53 (16), 43 (11), 41 (48), 39 (31), 29 (16), 28 (22), 27 (19).

syn-Tricyclo[4.2.1.1^{2,5}]decan-9-exo-ol (7). a) From **18**. Hydrogenation (H₂, 5% Pd/C) of 86 mg (0.57 mmol) of **18** in Et₂O and CC on 10 g of silica gel in pentane/Et₂O 2:1 gave 81 mg (93%) of **7**. M.p. 170–171°. IR: 3615*m*, 3400*w* (br.), 3000*w*, 2975*w*, 2935*s*, 1502*w*, 1483*w*, 1471*w*, 1451*w*, 1397*w* (br.), 1312*w*, 1226*w*, 1137*w*, 1077*s*, 1045*m*, 1017*w*, 982*m*, 955*w*, 914*w* (br.), 882*w* (br.), 843*w*, 676*w*. ¹H-NMR: 0.52 (*dt*, $J_{gem} = 11.5$, $J(2,10-exo) = J(5,10-exo) = 2.5$, $H_{exo-C(10)}$); 0.99 (*m*, $w_{1/2} \approx 5$, $exo-HO-C(9)$); 1.15–1.25 (*m*, $H_{exo-C(3)}$, $H_{exo-C(4)}$); 1.45–1.65 (*m*, $H_{exo-C(7)}$, $H_{exo-C(8)}$); 1.7–1.8 (*m*, $H_{endo-C(7)}$, $H_{endo-C(8)}$); 1.75–1.9 (*m*, $H_{endo-C(3)}$, $H_{endo-C(4)}$); 1.95 (*dm*, $J_{gem} = 11.5$, $w_{1/2} \approx 6$ each, $H_{endo-C(10)}$); 2.08 (*m*, $w_{1/2} \approx 18$, among others $J(1,2) = J(5,6) = 9.5$, $J(1,9-endo) = J(6,9-endo) = 2.5$, $H-C(1)$, $H-C(6)$); 2.35 (*m*, $w_{1/2} \approx 18$, among others $J(1,2) = J(5,6) = 9.5$, $J(2,10-exo) = J(5,10-exo) = 2.5$, $H-C(2)$, $H-C(5)$); 4.52 (*m*, $w_{1/2} \approx 5$, among others $J(1,9-endo) = J(6,9-endo) = 2.5$, $H_{endo-C(9)}$). ¹³C-NMR: 21.94 (*t*, C(3), C(4)); 26.05 (*t*, C(7), C(8)); 28.22 (*t*, C(10)); 36.27 (*d*, C(2), C(5)); 41.16 (*d*, C(1), C(6)); 73.25 (*d*, C(9)). MS: 152 (21, M^+ , C₁₀H₁₆O), 134 (11), 124 (11), 123 (57), 121 (26), 119 (23), 110 (19), 109 (100), 108 (13), 106 (17), 105 (19), 96 (11), 95 (34), 93 (58), 92 (32), 91 (36), 83 (16), 81 (36), 80 (31), 79 (61), 78 (14), 77 (21), 70 (18), 68 (10), 67 (52), 66 (18), 65 (11), 57 (20), 55 (25), 54 (11), 53 (15), 41 (40), 39 (29), 29 (12), 27 (18).

b) From **23**. A soln. of 171.5 mg (1.14 mmol) of **23** in 10 ml of *i*-PrOH was added under Ar dropwise and under vigorous stirring to a mixture of 500 mg (2.15 mmol) of Na (added as small pieces) and 20 ml of abs. toluene. After 4 h at reflux, workup (Et₂O, 2 × sat. (NH₄)₂SO₄, 2 × sat. NaCl soln.) and CC on 25 g of silica gel in pentane/CH₂Cl₂/Et₂O 3:2:1, 2.5 mg of reactant **23**, 76 mg (44%) of **7** and 87 mg (50%) of **8** (see below) were obtained.

syn-Tricyclo[4.2.1.1^{2,5}]decan-9-endo-ol (8). a) From **20**. Hydrogenation (H₂, 10% Pd/C) of 29 mg (0.19 mmol) of **20** in 20 ml of Et₂O for 3 h and CC on 5 g silica gel in pentane/Et₂O 3:1 led to 25.5 mg (87%) of **8**. IR: 3630*m*, 3000*w*, 2990*w* (sh), 2930*s*, 2880*m*, 1494*w*, 1475*m*, 1425*w*, 1315*w* (br.), 1268*w* (br.), 1215*w*, 1188*m*, 1148*m*, 1076*w*, 1023*w*, 848*w*, 716*w*, 650*w*. ¹H-NMR: 0.63 (*dt*, $J_{gem} = 11$, $J(2,10-exo) = J(5,10-exo) = 3$, $H_{exo-C(10)}$);

1.2–1.3 (*m*, H_{exo}-C(7), H_{exo}-C(8)); 1.25–1.4 (*m*, H_{exo}-C(3), H_{exo}-C(4)); 1.5–1.6 (*m*, H_{endo}-C(7), H_{endo}-C(8)); 1.6–1.7 (*m*, H_{endo}-C(3), H_{endo}-C(4)); 1.77 (*m*, *w*_{1/2} ≈ 4, endo-HO-C(9)); 2.15 (*m*, *w*_{1/2} ≈ 18, among others *J*(1,2) = *J*(5,6) = 9, *J*(1,9-*exo*) = *J*(6,9-*exo*) = 3, H-C(1), H-C(6)); 2.37 (*m*, *w*_{1/2} ≈ 18, among others *J*(1,2) = *J*(5,6) = 9, *J*(2,10-*exo*) = *J*(5,10-*exo*) = 3, H-C(2), H-C(5)); 2.86 (*dm*, *J*_{gem} = 11, *w*_{1/2} ≈ 6 each, H_{endo}-C(10)); 3.63 (*t*, *J*(1,9-*exo*) = *J*(6,9-*exo*) = 3, H_{exo}-C(9)). ¹³C-NMR: 23.08 (*t*, C(3), C(4)); 26.83 (*t*, C(7), C(8)); 30.12 (*t*, C(10)); 35.73 (*d*, C(2), C(5)); 40.25 (*d*, C(1), C(6)); 75.49 (*d*, C(9)). MS: 152 (6.3, *M*⁺, C₁₀H₁₆O), 123 (15), 109 (27), 93 (17), 91 (12), 81 (10), 79 (17), 67 (18), 41 (11), 32 (26), 28 (100).

b) From **23**. A soln. of 21 mg (0.14 mmol) of **23** in 2 ml of Et₂O was treated under Ar with 20 mg (0.5 mmol) of LiAlH₄. Stirring (2 h) at r.t. and workup (sat. (NH₄)₂SO₄ soln., filtration through *Celite*) gave 20.5 mg (96%) of **8**. M.p. 199–204°.

anti-*Tricyclo[4.2.1.1^{2,5}]decan-3-*exo*-ol* (**9**). IR: 3620*m*, 3400*w* (br.), 2995*m*, 2950*m*, 2925*s*, 2870*m*, 1487*w*, 1476*m*, 1457*m*, 1438*w*, 1327*w*, 1307*w*, 1291*w*, 1276*w*, 1272*w*, 1237*w*, 1205*w*, 1160*w*, 1116*w*, 1079*m*, 1049*m*, 1013*s*, 998*m*, 952*w*, 910*w*, 903*w*, 896*w*, 841*w*. ¹H-NMR: 0.90 (*dm*, *J*_{gem} = 11.5, *w*_{1/2} ≈ 8 each, H_{exo}-C(9)); 1.31 (*dm*, *J*_{gem} = 11.5; *w*_{1/2} ≈ 10 each, H_{exo}-C(10)); 1.37 (*ddd*, *J*_{gem} = 13.5, *J*(4-*exo*, 5) = 5.5, *J*(3-*endo*, 4-*exo*) = 2, H_{exo}-C(4)); 1.4–1.75 (*m*, 2 H-C(7), 2 H-C(8), H_{endo}-C(9)); 1.81 (*dm*, *J*_{gem} = 11.5, *w*_{1/2} ≈ 7 each, H_{endo}-C(10)); 1.83, 1.94, 2.04, 2.11 (4 *m*, *w*_{1/2} ≈ 8, *w*_{1/2} ≈ 13, *w*_{1/2} ≈ 13, *w*_{1/2} ≈ 12, H-C(1), H-C(2), H-C(5), H-C(6)); 2.20 (*ddd*, *J*_{gem} = 13.5, *J*(3-*endo*, 4-*endo*) = 6.5, *J*(4-*endo*, 10-*endo*) = 3, H_{endo}-C(4)); 4.26 (*ddd*, *J*(3-*endo*, 4-*endo*) = 6.5, *J*(3-*endo*, 4-*exo*) = 2, *J*(3-*endo*, 10-*endo*) = 1.5, H_{endo}-C(3)). MS: 152 (12, *M*⁺, C₁₀H₁₆O), 134 (53), 123 (11), 119 (13), 108 (37), 107 (10), 106 (14), 105 (16), 95 (10), 93 (30), 92 (18), 91 (20), 81 (23), 80 (100), 79 (66), 78 (15), 77 (16), 67 (40), 57 (10), 55 (35), 54 (13), 53 (10), 41 (30), 39 (20), 29 (11), 27 (12).

anti-*Tricyclo[4.2.1.1^{2,5}]decan-3-*endo*-ol* (**10**). A soln. of 78 mg (0.5 mmol) of **31** in 15 ml of Et₂O was treated with a small amount of LiAlH₄. Stirring for 1 1/2 h at r.t., workup (sat. (NH₄)₂SO₄ soln., filtration through *Celite*) and twice CC on 5 g of silica gel, once in pentane/Et₂O 3:1 and once in pentane/Et₂O 10:1 yielded 55.5 mg (70%) of **10**. IR (CDCl₃): 3610*m*, 2995*w*, 2945*m*, 2925*s*, 1475*w*, 1455*w*, 1377*w*, 1345*w*, 1293*w*, 1240*w*, 1180*w*, 1154*w*, 1045*m*, 1029*m*, 982*m*. ¹H-NMR: 1.02 (*dm*, *J*_{gem} = 11.5, *w*_{1/2} ≈ 9, H_{exo}-C(10)); 1.06 (*dm*, *J*_{gem} = 11.5, *w*_{1/2} ≈ 9, H_{exo}-C(9)); 1.60 (*dt*, *J*_{gem} = 13, *J*(3-*exo*, 4-*endo*) = *J*(4-*endo*, 10-*endo*) = 4, H_{endo}-C(4)); 1.55–1.8 (*m*, 2 H-C(7), 2 H-C(8)); 1.77 (*m*, *w*_{1/2} ≈ 4, endo-HO-C(3)); 1.89 (*dd*, *J*_{gem} = 11.5, *J*(4-*endo*, 10-*endo*) = 4, H_{endo}-C(10)); 1.9–2.1 (*m*, H-C(1) or H-C(6), H-C(2), H_{exo}-C(4), H-C(5)); 2.15 (*m*, *w*_{1/2} ≈ 12, H-C(1) or H-C(6)); 2.49 (*dm*, *J*_{gem} = 11.5, *w*_{1/2} ≈ 5 each, H_{endo}-C(9)); 4.46 (*ddd*, *J*(3-*exo*, 4-*exo*) = 10, *J*(2,3-*exo*) = 5, *J*(3-*exo*, 4-*endo*) = 4, H_{exo}-C(3)). ¹³C-NMR: 29.48, 30.25, 31.85 (3 *t*, C(7), C(8), C(10)); 34.32 (*t*, C(9)); 35.80 (*d*, C(6)); 38.00 (*t*, C(4)); 38.66, 39.32 (2 *d*, C(1), C(5)); 44.37 (*d*, C(2)); 76.64 (*d*, C(3)).

anti-*Tricyclo[4.2.1.1^{2,5}]decan-9-*exo*-ol* (**11**). a) From **24**. Hydrogenation (H₂, 5% Pd/C) of 102 mg (0.68 mmol) of **24** in 10 ml of Et₂O and CC on 10 g of silica gel in pentane/Et₂O 3:1 gave 96 mg (93%) of **11**. M.p. 175–177° (sublimation). IR: 3625*m*, 3460*w*, 2995*w* (sh), 2945*s* (sh), 2930*s*, 2875*m*, 1485*w*, 1467*m*, 1451*w*, 1336*w*, 1314*w*, 1292*w*, 1278*w*, 1189*w*, 1162*w*, 1133*w* (br.), 1061*s*, 1049*m*, 992*w*, 971*s*, 933*w*, 871*w*, 858*w*, 709*w*. ¹H-NMR: 0.82 (*dm*, *J*_{gem} = 11.5, *w*_{1/2} ≈ 2 each, H_{exo}-C(10)); 1.17 (*m*, *w*_{1/2} ≈ 4, *exo*-HO-C(9)); 1.4–1.65 (*m*, 2 H-C(3), 2 H-C(4), H_{endo}-C(7), H_{endo}-C(8)); 1.65–1.75 (*m*, H_{exo}-C(7), H_{exo}-C(8)); 1.82 (*dm*, *J*_{gem} = 11.5, *w*_{1/2} ≈ 6, H_{endo}-C(10)); 1.9–2.1 (*m*, H-C(1), H-C(2), H-C(5), H-C(6)); 4.18 (*m*, *w*_{1/2} ≈ 4, H_{endo}-C(9)). ¹³C-NMR: 25.95 (*t*, C(3), C(4)); 28.76 (*t*, C(7), C(8)); 30.31 (*t*, C(10)); 39.21 (*d*, C(2), C(5)); 45.68 (*d*, C(1), C(6)); 75.02 (*d*, C(9)). MS: 152 (100, *M*⁺, C₁₀H₁₆O), 134 (25), 124 (15), 123 (54), 121 (41), 119 (28), 110 (21), 109 (69), 108 (20), 106 (27), 105 (25), 96 (24), 95 (47), 94 (15), 93 (71), 92 (55), 91 (42), 84 (11), 83 (27), 82 (11), 81 (39), 80 (58), 79 (76), 78 (23), 77 (25), 70 (32), 69 (14), 68 (19), 67 (79), 66 (35), 65 (14), 57 (38), 56 (10), 55 (39), 54 (20), 53 (24), 51 (10), 43 (14), 41 (63), 39 (40), 29 (19), 28 (10), 27 (25).

b) From **29**. A soln. of 201 mg (1.34 mmol) of **29** in 10 ml of *i*-PrOH was added under Ar dropwise and under vigorous stirring to a mixture of 400 mg (17 mmol) of Na (added in small pieces) and 20 ml of abs. toluene. After 4 h at reflux, workup (Et₂O, 2 × sat. (NH₄)₂SO₄, 2 × sat. NaCl soln.) and CC on 20 g of silica gel in pentane/Et₂O 4:1, 44.5 mg **29**, 122.5 mg (60% or 77% with respect to converted **29**) of **11** and 6 mg (3% or 4% with respect to converted **29**) of **12** were obtained.

anti-*Tricyclo[4.2.1.1^{2,5}]decan-9-*endo*-ol* (**12**). M.p. 201–203° (after sublimation at 63°/0.02 Torr). IR: 3620*m*, 3480*w* (br.), 1482*w*, 1460*m*, 1375*w*, 1345*m*, 1320*w*, 1277*m*, 1176*m*, 1168*m*, 1147*w*, 1115*w*, 1083*m*, 1072*w*. ¹H-NMR: 1.04 (*dm*, *J*_{gem} = 11.5, *w*_{1/2} ≈ 8 each, H_{exo}-C(10)); 1.45–1.65 (*m*, H_{exo}-C(3), H_{exo}-C(4), 2 H-C(7), 2 H-C(8)); 1.75 (*m*, *w*_{1/2} ≈ 3, endo-HO-C(9)); 1.84 (*m*, *w*_{1/2} ≈ 12, H-C(1), H-C(6)); 2.05 (*m*, *w*_{1/2} ≈ 12, H-C(2), H-C(5)); 2.14 (*dm*, *J*_{gem} = 11.5, *w*_{1/2} ≈ 6 each, H_{endo}-C(10)); 2.3–2.4 (*m*, H_{endo}-C(3), H_{endo}-C(4)); 3.88 (*m*, *w*_{1/2} ≈ 9, H_{exo}-C(9)). MS: 152 (73, *M*⁺, C₁₀H₁₆O), 134 (20), 124 (12), 123 (47), 121 (32), 119 (30), 110 (18), 109 (67), 108 (18), 106 (32), 105 (26), 96 (16), 95 (34), 94 (12), 93 (72), 92 (55), 91 (52), 83 (23), 81 (37), 80 (55), 79 (77), 78 (27), 77 (24), 70 (22), 68 (18), 67 (100), 66 (48), 65 (13), 57 (33), 55 (33), 54 (15), 53 (19), 41 (54), 39 (33), 29 (17), 27 (20).

2-endo,3-endo-Trimethylene-8,9,10-trinorborn-1'-ene (**13**). To a stirred suspension of 600 mg (3.1 mmol) of potassium azodicarboxylate (PADA) in 3 ml of CH₃OH, 196 mg (1.5 mmol) of *endo*-dicyclopentadiene was added under Ar. After 30 min at r.t., 500 μ l (8.75 mmol) of AcOH were added over 15 min. After further 15 min of stirring, the mixture was worked up (pentane, 1 \times 2N HCl, 1 \times sat. NaHCO₃, 1 \times sat. NaCl soln.). Cap. GLC (*SE* 52) showed reactant/**13/3** in the ratio of 3:88:5. Prep. GLC (10% NPGS) yielded 125 mg (64%) of **13**. IR: 3040m, 2930s, 2890w, 2860m, 2840m, 1606w, 1465m, 1450m, 1443s, 1351m, 1321m, 1311m, 1290m, 1271m, 1258w, 1241w, 1209w, 1182w, 1155w, 1145m, 1071w, 1035w, 941s, 916w, 891w, 877w, 679s, 666s. ¹H-NMR: 1.15–1.3 (m, 2 H–C(5), 2 H–C(6)); 1.40 (dt, $J_{gem} = 9$, $J(1,7^{C(5)}) = J(4, 7^{C(5)}) = 1$, H^{C(5)}–C(7)); 1.47 (dtt, $J_{gem} = 9$, $J(1,7^{C(2)}) = J(4, 7^{C(2)}) = 2$, $J(5-endo, 7^{C(2)}) = J(6-endo, 7^{C(2)}) \approx 2$, H^{C(2)}–C(7)); 2.12 (m, $w_{1/2} \approx 10$, H–C(4)); 2.15–2.3 (m, 2 H–C(3')); 2.27 (m, $w_{1/2} \approx 11$, H–C(1)); 2.53 (dtt, $J(2-exo, 3-exo) = 10.5$, $J(3-exo, 3'-exo) = 8.5$, $J(3-exo, 4) = J(3-exo, 3'-endo) = 4.5$, H_{exo}–C(3)); 3.00 (m, $w_{1/2} \approx 20$, among others $J(2-exo, 3-exo) = 10.5$, $J(1, 2-exo) = 5$, $J(2-exo, 1') = J(2-exo, 2') = 2$, H_{exo}–C(2)); 5.55 and 5.65 (2 dq, $J(1', 2') = 5.5$, $J(2-exo, 1') = J(1', 3'-endo) = J(1', 3'-exo) = 2$, and $J(2-exo, 2') = J(2', 3'-endo) = J(2', 3'-exo) = 2$, H–C(1') und H–C(2')). ¹³C-NMR: 21.98 (t, C(5)); 25.23 (t, C(6)); 32.26 (t, C(3')); 39.53 (d, C(1)); 40.95 (d, C(4)); 41.15 (t, C(7)); 42.40 (d, C(3)); 52.94 (d, C(2)); 130.36 (d, C(2')); 132.96 (d, C(1')).

2-exo,3-exo-Trimethylene-8,9,10-trinorborn-1'-ene (**14**). Hydrogenation (H₂, 10% Pd/C) of 20 mg (0.15 mmol) of *exo*-dicyclopentadiene in 5 ml of pentane for 30 min gave a mixture of **14** and **4** (ratio 87:13, determined by cap. GLC (*SE* 52) in almost quant. yield¹⁶). IR (CDCl₃): 3040m, 2940s, 2865m, 2835m, 1610w, 1447m, 1438m, 1350m, 1317w, 1299m, 1291w, 1264w, 1190w, 1122w, 1045w (br.), 965w, 785w. ¹H-NMR: 0.95 (dq_{int.}, $J_{gem} = 10$, $J(1, 7^{C(5)}) = J(2-endo, 7^{C(5)}) = J(3-endo, 7^{C(5)}) = J(4, 7^{C(5)}) = 1.5$, H^{C(5)}–C(7)); 1.1–1.28 (m, H_{exo}–C(5), H_{exo}–C(6)); 1.32 (dq_{int.}, $J_{gem} = 10$, $J(1, 7^{C(2)}) = J(4, 7^{C(2)}) = J(5-exo, 7^{C(2)}) = J(6-exo, 7^{C(2)}) = 2$, H^{C(2)}–C(7)); 1.37–1.57 (m, H_{endo}–C(5), H_{endo}–C(6)); 1.88 (dm, $J_{gem} = 15$, $w_{1/2} \approx 10$ each, H_{exo}–C(3')); 1.92 and 1.98 (2 m, $w_{1/2} \approx 7$ each, H–C(1), H–C(4)); 2.11 (dddd, $J(2-endo, 3-endo) = 10$, $J(3-endo, 3'-endo) = 7.5$, $J(3-endo, 3'-exo) = 3.5$, $J(3-endo, 7^{C(5)}) = 1.5$, H_{endo}–C(3)); 2.56 (m, among others $J(2-endo, 3-endo) = 10$, H_{endo}–C(2)); 2.57 (ddm, $J_{gem} = 15$, $J(3-endo, 3'-endo) = 7.5$, $w_{1/2} \approx 6$ each, H_{endo}–C(3')); 5.47 (ddddm, $J(1', 2') = 5.5$, 3 $J = 3$ each, H–C(1') or H–C(2')); 5.65 (ddddm, $J(1', 2') = 5.5$, 3 $J = 2.5$ each, H–C(1') or H–C(2')). ¹³C-NMR: 28.84, 29.17, (2 t, C(5), C(6)); 31.66 (t, C(7)); 39.78 (t, C(3')); 40.49 (d, C(1)); 43.15 (d, C(4)); 43.89 (d, C(3)); 55.80 (d, C(2)); 131.81, 132.63 (2 d, C(1'), C(2')).

syn-Tricyclo[4.2.1.1^{2,5}]dec-3-en-9-*exo*-ol (**18**). To a soln. of 108 mg (0.73 mmol) of **16** in 4 ml of abs. toluene under Ar, 300 mg (13 mmol) of Na in small pieces and dropwise 1 ml of *i*-PrOH were added. After 4 h of reflux, workup (Et₂O, 2 \times sat. (NH₄)₂SO₄, 2 \times sat. NaCl soln.) and CC on 15 g of silica gel in pentane/Et₂O/CH₂Cl₂ 3:1:1 gave 8 mg of **16**, 18 mg (16.5%) of **20** (see below) and 71.5 mg (66.5% or 70.5% with respect to converted **16**) of **18**. IR: 3630m, 3490w (br.), 3060m, 3020m, 2950s, 2875m, 1655w (br.), 1578w (br.), 1497w, 1460w (br.), 1441w, 1348m, 1308w, 1263w, 1236w, 1096m, 1076s, 1047s, 1013m, 971m, 930m, 881w, 850m. ¹H-NMR: 0.99 (dt, $J_{gem} = 10.5$, $J(2, 10-exo) = J(5, 10-exo) = 3$, H_{exo}–C(10)); 1.22 (m, $w_{1/2} \approx 8$, *exo*–HO–C(9)); 1.3–1.65 (m, 2H–C(7), 2 H–C(8)); 1.97 (dtm, $J_{gem} = 10.5$, $J(2, 10-endo) = J(5, 10-endo) = 1.5$, $J(3, 10-endo) = J(4, 10-endo) < 0.5$, H_{endo}–C(10)); 2.25 (m, $w_{1/2} \approx 17$, among others $J(1, 2) = J(5, 6) = 9$, H–C(1), H–C(6)); 2.67 (dddm, $J(1, 2) = J(5, 6) = 9$, $J(2, 10-exo) = J(5, 10-exo) = 3$, $J(2, 10-endo) = J(5, 10-endo) = 1.5$, $J(2, 3) = J(4, 5) < 0.5$, H–C(2), H–C(5)); 4.69 (m, $w_{1/2} \approx 8$, H_{endo}–C(9)); 6.29 (m, $w_{1/2} \approx 5$, H–C(3), H–C(4)). ¹³C-NMR: 24.14 (t, C(7), C(8)); 33.56 (t, C(10)); 40.46, 42.02 (2 d, C(1), C(2), C(5), C(6)); 74.58 (d, C(9)); 139.71 (d, C(3), C(4)). MS: 150 (12, M⁺, C₁₀H₁₄O), 132 (18), 121 (11), 119 (14), 117 (31), 108 (16), 107 (10), 105 (11), 104 (48), 96 (16), 94 (15), 93 (40), 92 (20), 91 (75), 84 (66), 83 (49), 82 (26), 81 (15), 80 (29), 79 (74), 78 (27), 77 (63), 70 (13), 67 (56), 66 (100), 65 (29), 57 (25), 55 (21), 53 (18), 51 (19), 41 (33), 40 (11), 39 (13), 29 (13), 27 (24).

syn-Tricyclo[4.2.1.1^{2,5}]dec-3-en-9-*exo*-yl Acetate (**19**). A soln. of 15 mg (0.09 mmol) of **18** in 2 ml of Ac₂O/pyridine 1:1 was kept for 24 h at r.t. Cooling to 0°, addition of 5 ml of ice/H₂O, stirring for 30 min, workup (Et₂O, 3 \times 2N HCl, 2 \times 1M NaHCO₃, 1 \times sat. NaCl soln.) and CC on 3 g of silica gel in pentane/Et₂O 3:1 yielded 18.5 mg (96%) of **19**. IR: 3055w, 2950s, 2865w, 1728s, 1457w, 1438w, 1388w, 1363m, 1336w, 1318w, 1309w, 1263m, 1259m (sh), 1237s, 1193w, 1096w, 1058w, 1040m, 1017m, 991w, 968w, 927w, 878w, 837w. ¹H-NMR: 1.08 (dt, $J_{gem} = 10.5$, $J(2, 10-exo) = J(5, 10-exo) = 3$, H_{exo}–C(10)); 1.3–1.55 (m, 2 H–C(7), 2 H–C(8)); 1.96 (s, CH₃COO–C(9)); 2.05 (dm, $J_{gem} = 10.5$, $w_{1/2} \approx 3$ each, H_{endo}–C(10)); 2.40 (m, $w_{1/2} \approx 17$, among others $J(1, 2) = J(5, 6) = 9$, H–C(1), H–C(6)); 2.72 (m, $w_{1/2} \approx 16$, among others $J(1, 2) = J(5, 6) = 9$, H–C(2), H–C(5)); 5.60 (m, $w_{1/2} \approx 4$, H_{endo}–C(9)); 6.31 (m, $w_{1/2} \approx 5$, H–C(3), H–C(4)). MS: 192 (2, M⁺, C₁₂H₁₆O₂), 132 (16), 126 (12), 117 (12), 91 (18), 84 (16), 83 (10), 79 (12), 77 (10), 67 (55), 66 (87), 43 (56), 41 (11), 32 (24), 28 (100).

¹⁶) Compound **14** can also be prepared by PADA reduction of *exo*-dicyclopentadiene.

syn-Tricyclo[4.2.1.1^{2,5}]dec-3-en-9-endo-ol (**20**). A soln. of 52 mg (0.35 mmol) of **16** in 5 ml of Et₂O were treated with 30 mg (0.8 mmol) of LiAlH₄ and stirred for 2 h at r.t. Workup (sat. (NH₄)₂SO₄ soln. filtration through *Celite*) and CC on 5 g of silica gel in pentane/Et₂O 2:1 gave 46 mg (88%) of **20**. M.p. 131–132° (sublimation). IR: 3630m, 3320m (br.), 3050m, 2930s, 2870m, 2795w, 1652w, 1644w (sh), 1577w, 1460m, 1443m, 1339m, 1318w, 1298w, 1288m, 1256m, 1177s, 1162m, 1121w, 1093m, 1076s, 1056m, 1022w, 994w, 980w, 921w, 897w, 883w (sh), 874m, 860w, 722w, 659m. ¹H-NMR: 1.35–1.55 (m, 2 H–C(7), 2 H–C(8), H_{exo}–C(10)); 1.94 (s, w_{1/2} ≈ 3, endo–HO–C(9)); 2.24 (dtt, J(1,2) = J(5,6) = 9, J(1,9-*exo*) = J(6,9-*exo*) = 3.5, J(1,8-*endo*) = J(1,8-*exo*) = J(6,7-*endo*) = J(6,7-*exo*) = 2, H–C(1), H–C(6)); 2.64 (dt, J(1,2) = J(5,6) = 9, J(2,10-*endo*) = J(5,10-*endo*) = 1.5, J(2,3) = J(4,5) = 1.5, H–C(2), H–C(5)); 3.24 (dtm, J_{gem} = 9.5, J(2,10-*endo*) = J(5,10-*endo*) = 1.5, J(3,10-*endo*) = J(4,10-*endo*) < 0.5, H_{endo}–C(10)); 4.09 (t, J(1,9-*exo*) = J(6,9-*exo*) = 3.5, H_{exo}–C(9)); 6.47 (tm, J(2,3) = J(4,5) = 1.5, J(3,10-*endo*) = J(4,10-*endo*) < 0.5, H–C(3), H–C(4)). ¹³C-NMR: 26.22 (t, C(7), C(8)); 36.81 (t, C(10)); 40.37, 40.47 (2 d, C(1), C(2), C(5), C(6)); 79.75 (d, C(9)); 143.28 (d, C(3), C(4)). MS: 132 (31, M⁺, C₁₀H₁₄O), 117 (24), 93 (20), 91 (37), 84 (10), 83 (21), 80 (15), 79 (33), 78 (14), 77 (25), 67 (60), 66 (100), 65 (11), 57 (16), 55 (11), 41 (18), 39 (20), 27 (11).

syn-Tricyclo[4.2.1.1^{2,5}]dec-3-en-9-endo-yl Acetate (**21**). A soln. of 10 mg (0.07 mmol) of **20** in 2 ml of Ac₂O/pyridine 1:1 was kept for 18 h at r.t. workup (ice/H₂O, Et₂O, 3 × 2N HCl, 2 × 1N NaHCO₃, 1 × sat. NaCl soln.) and CC on 3 g of silica gel in pentane/Et₂O 3:1 yielded 12 mg (95%) of **21**. IR: 3045w, 2955s, 2910m, 2875w, 1737s, 1476m, 1463m, 1446w, 1422w (br.), 1367s, 1340m, 1332w, 1292m, 1273w, 1255w (sh), 1241s, 1197m, 1171s, 1159s, 1124w, 1096m, 1066s, 1046s, 927m, 898w, 885w, 875m, 860w, 684w, 652w. ¹H-NMR: 1.4–1.65 (m, 2 H–C(7), 2 H–C(8), H_{exo}–C(10)); 2.09 (s, endo–CH₃COO–C(9)); 2.45 (m, w_{1/2} ≈ 17, H–C(1), H–C(6)); 2.62 (m, w_{1/2} ≈ 16, H–C(2), H–C(5)); 2.76 (dm, J_{gem} = 10, w_{1/2} ≈ 3 each, H_{endo}–C(10)); 4.73 (t, J(1,9-*exo*) = J(6,9-*exo*) = 3, H_{exo}–C(9)); 6.45 (m, w_{1/2} ≈ 5, H–C(3), H–C(4)). ¹³C-NMR: 21.78 (q, endo–CH₃COO–C(9)); 25.59 (t, C(7), C(8)); 37.20 (t, C(10)); 38.28, 40.09 (2 d, C(1), C(2), C(5), C(6)); 79.98 (d, C(9)); 142.83 (d, C(3), C(4)); 170.66 (s, endo–CH₃COO–C(9)). MS: 192 (0.4, M⁺, C₁₂H₁₆O₂), 132 (21), 131 (10), 117 (20), 104 (11), 91 (21), 86 (51), 84 (79), 79 (11), 78 (20), 77 (10), 67 (31), 66 (48), 49 (12), 47 (17), 43 (31), 39 (10), 32 (23), 28 (100).

syn-Tricyclo[4.2.1.1^{2,5}]dec-9-*exo*-yl Acetate (**22**). a) From **7**. A soln. of 30 mg (0.2 mmol) of **7** in 5 ml of Ac₂O/pyridine 1:1 and a catalytical amount of 4-(*N,N*-dimethylamino)pyridine was kept for 18 h at r.t. Workup (ice/H₂O, Et₂O, 3 × 2N HCl, 2 × 1N NaHCO₃, 1 × sat. NaCl soln.) and twice CC on 3 g of silica gel in pentane/Et₂O 19:1 gave 27.5 mg (72%) of **22**. IR: 3030w, 2995m, 2930s, 2920s, 2880w, 2865w, 1752w, 1724s, 1496w, 1480m, 1467w, 1448m, 1386w, 1359s, 1318w, 1308m, 1294w, 1238s, 1192w, 1140w, 1107w, 1056m, 1031s, 1017m, 951w, 929m, 904w, 879w. ¹H-NMR: 0.59 (dt, J_{gem} = 12, J(2,10-*exo*) = J(5,10-*exo*) = 3, H_{exo}–C(10)); 1.15–1.3 (m, H_{exo}–C(3), H_{exo}–C(4)); 1.4–1.5 (m, H_{exo}–C(7), H_{exo}–C(8)); 1.7–1.8 (m, H_{endo}–C(7), H_{endo}–C(8)); 1.75–1.85 (m, H_{endo}–C(3), H_{endo}–C(4)); 1.97 (s, *exo*–CH₃COO–C(9)); 2.02 (dm, J_{gem} = 12, w_{1/2} ≈ 6 each, H_{endo}–C(10)); 2.24 (m, w_{1/2} ≈ 18, among others J(1,2) = J(5,6) = 9.5, J(1,9-*endo*) = J(6,9-*endo*) ≈ 2.5, H–C(1), H–C(6)); 2.41 (m, w_{1/2} ≈ 18, among others J(1,2) = J(5,6) = 9.5, J(2,10-*exo*) = J(5,10-*exo*) = 3, H–C(2), H–C(5)); 5.37 (m, w_{1/2} ≈ 5, among others J(1,9-*endo*) = J(6,9-*endo*) ≈ 2.5, H_{endo}–C(9)). ¹³C-NMR: 21.44 (q, CH₃COO–C(9)); 22.48 (t, C(3), C(4)); 25.85 (t, C(7), C(8)); 28.47 (t, C(10)); 36.27 (d, C(2), C(5)); 38.86 (d, C(1), C(6)); 77.67 (d, C(9)); 171.16 (s, CH₃COO–C(9)).

b) From **19**. Hydrogenation (H₂, 10% Pd/C) of 11.5 mg (0.06 mmol) of **19** in Et₂O for 2 h at r.t. yielded 9.5 mg (82%) **22**.

anti-Tricyclo[4.2.1.1^{2,5}]dec-3-en-9-*exo*-ol (**24**). To a suspension of 100 mg (4.3 mmol) of Na (added in small pieces) in 8 ml of abs. toluene, a soln. of 103 mg (0.7 mmol) of **17** in 4 ml of *i*-PrOH was added dropwise under Ar. After 4 h at reflux, workup (Et₂O, 2 × sat. (NH₄)₂SO₄, 2 × sat. NaCl soln.) and CC on 10 g of silica gel in pentane/Et₂O/CH₂Cl₂ 6:2:1 afforded 11 mg of **17**, 6.5 mg (6.5%) of **26**, 4.5 mg (4.3% or 48% with respect to converted **17**) of **24** and 18.5 mg (17.5%) of **27** (see below) as well as 8 mg (13%) of a 1:1 mixture of **24/27**. **24**: m.p. 149–150°. IR: 3615m, 3480w (br.), 3050w, 3000m, 2935s, 2890w, 2875m, 1478w, 1449w, 1332m, 1319w, 1284w, 1259w, 1226m, 1188w, 1094m, 1057s, 1041s, 991m, 962m, 959m (sh.), 913w, 900w, 887w, 850m, 709s. ¹H-NMR: 1.07 (m, w_{1/2} ≈ 6, *exo*–HO–C(9)); 1.15 (dtm, J_{gem} = 10.5, J(2,10-*exo*) = J(5,10-*exo*) = 3.5, w_{1/2} ≈ 2, H_{exo}–C(10)); 1.45–1.55 (m, H_{endo}–C(7), H_{endo}–C(8)); 1.69 (dm, J_{gem} = 10.5, w_{1/2} ≈ 3 each, H_{endo}–C(10)); 1.75–1.9 (m, H_{exo}–C(7), H_{exo}–C(8)); 2.49 (m, w_{1/2} ≈ 11, H–C(1), H–C(2), H–C(5), H–C(6)); 3.84 (m, w_{1/2} ≈ 6, H_{endo}–C(9)); 5.82 (m, w_{1/2} ≈ 4, H–C(3), H–C(4)). ¹³C-NMR: 26.72 (t, C(10)); 38.05 (t, C(7), C(8)); 38.18 (d, C(1), C(6)); 43.78 (d, C(2), C(5)); 77.29 (d, C(9)); 131.83 (d, C(3), C(4)). MS: 150 (5, M⁺, C₁₀H₁₄O), 95 (11), 93 (18), 91 (22), 84 (100), 83 (65), 82 (13), 80 (11), 79 (24), 77 (21), 67 (30), 66 (35), 57 (11), 55 (11), 41 (15), 39 (18), 27 (10).

anti-Tricyclo[4.2.1.1^{2,5}]dec-3-en-9-*exo*-yl Acetate (**25**). A soln. of 19 mg (0.12 mmol) of **24** in 4 ml of Ac₂O/pyridine 1:1 and a catalytical amount of 4-(*N,N*-dimethylamino)pyridine was kept for 5 h at r.t. Workup (ice/H₂O, Et₂O, 3 × 2N HCl, 2 × 1N NaHCO₃, 1 × sat. NaCl soln.) and CC on 2 g of silica gel in pentane/Et₂O 6:1

gave 19.5 mg (83%) of **25**. IR: 3050w, 3000m, 2950s, 2895w, 2880m, 1727s, 1479w, 1451m, 1430w, 1376m, 1362s, 1336m, 1322m, 1314w, 1301w, 1249s, 1219s, 1184w, 1098m, 1049w, 1031s, 1006m, 992m, 967m, 917w, 899w, 891w, 846w, 715m, 705w, 659w. ¹H-NMR: 1.19 (*dtm*, $J_{gem} = 10.5$, $J(2,10-exo) = J(5,10-exo) = 3.5$, $w_{1/2} \approx 2$ each, $H_{exo-C(10)}$); 1.5–1.6 (*m*, $H_{endo-C(7)}$, $H_{endo-C(8)}$); 1.65–1.85 (*m*, $H_{exo-C(7)}$, $H_{exo-C(8)}$); 1.96 (*s*, $exo-CH_3COO-C(9)$); 1.99 (*m*, $w_{1/2} \approx 13$, $H-C(1)$, $H-C(6)$); 2.52 (*m*, $w_{1/2} \approx 12$, $H-C(2)$, $H-C(5)$); 4.80 (*m*, $w_{1/2} \approx 5$, $H_{endo-C(9)}$); 5.92 (*m*, $w_{1/2} \approx 4$, $H-C(3)$, $H-C(4)$). ¹³C-NMR: 21.46 (*q*, $exo-CH_3COO-C(9)$); 27.03 (*t*, $C(10)$); 35.96 (*d*, $C(1)$, $C(6)$); 40.48 (*t*, $C(7)$, $C(8)$); 43.56 (*d*, $C(2)$, $C(5)$); 81.21 (*d*, $C(9)$); 132.03 (*d*, $C(3)$, $C(4)$); 170.62 (*s*, $exo-CH_3COO-C(9)$). MS: 192 (10, M^+ , $C_{12}H_{16}O_2$), 132 (56), 131 (11), 126 (16), 117 (21), 104 (17), 93 (13), 91 (27), 84 (36), 83 (22), 79 (17), 77 (15), 67 (100), 66 (95), 65 (10), 43 (81), 41 (16), 39 (16).

Tetracyclo[5.3.0^{2,6}.0^{3,9}]decan-2-ol (27). IR: 3605m, 3300m (br.), 2940s, 2855m, 1469m, 1452m, 1441w, 1333s, 1313m, 1270s, 1265m, 1254m, 1237w, 1183w, 1168m, 1150m, 1099s, 1072s, 1031m, 986m, 956w, 938m, 921m, 913w, 871w, 856w, 622w. ¹H-NMR: 1.08 (*ddt*, $J_{gem} = 12$, $J(7,8-exo) = 6.5$, $J(3 \text{ or } 6,8-exo) = J(8-exo,9) = 2$, $H_{exo-C(8)}$); 1.27 (*dm*, $J_{gem} = 10.5$, $w_{1/2} \approx 4$ each, among others $J(9,10-exo) = 1.5$, $J(1,10-exo) = 1$, $H_{exo-C(10)}$); 1.54 (*dm*, $J_{gem} = 12$, $w_{1/2} \approx 4$ each, among others $J(8-endo,10-endo) = 1$, $J(8-endo,9) \approx 1$, $H_{endo-C(8)}$); 1.5–1.65 (*m*, $H_{endo-C(4)}$, $H_{endo-C(5)}$); 1.67 (*m*, $w_{1/2} \approx 2$, $HO-C(2)$); 1.7–2.05 (*m*, $H_{exo-C(4)}$, $H_{exo-C(5)}$); 1.79 (*dm*, $J_{gem} = 10.5$, $w_{1/2} \approx 4$ each, among others $J(1,10-endo) = J(8-endo,10-endo) = 1$, $J(9,10-endo) = 0.5$, $H_{endo-C(10)}$); 2.1–2.25 (*m*, $H-C(3)$ or $H-C(6)$, $H-C(9)$); 2.54 (*ddm*, $J = 8$, $J = 6$, $w_{1/2} \approx 3$ each, $H-C(3)$, or $H-C(6)$); 2.61 (*dm*, $J(1,7) = 6$, $w_{1/2} \approx 3$ each, among others $J(1,10-endo) = J(1,10-exo) = 1$, $H-C(1)$). ¹³C-NMR: 27.18, 27.51, 27.62, 38.95 (4 *t*, $C(4)$, $C(5)$, $C(8)$, $C(10)$); 28.86, 43.02, 46.74, 50.75, 55.55 (5 *d*, $C(1)$, $C(3)$, $C(6)$, $C(7)$, $C(9)$); 77.23 (*s*, $C(2)$). MS: 150 (4, M^+ , $C_{10}H_{14}O$), 95 (32), 84 (99), 83 (100), 82 (23), 79 (12), 67 (26), 66 (11), 55 (16), 39 (12).

anti-Tricyclo[4.2.1.1^{2,5}]dec-9-oxo-yl Acetate (28). a) From **11**. A soln. of 100 mg (0.66 mmol) of **11** in 10 ml of Ac_2O /pyridine and a catalytical amount of 4-(*N,N*-dimethylamino)pyridine was kept for 18 h at r.t. Workup (ice/ H_2O , Et_2O , $3 \times 2N HCl$, $2 \times 1N NaHCO_3$, $1 \times sat. NaCl$ soln.) and CC on 30 g of silica gel in pentane/ Et_2O 19:1 yielded 120.5 mg (94.5%) of **28**. IR: 2995w, 2940s (br.), 2880m, 1739m (sh), 1724s, 1487w, 1468w, 1449w, 1393w, 1363m, 1336w, 1314w, 1299w, 1281w, 1243s, 1212w, 1192m, 1166w, 1056w, 1033m, 1011w, 992w, 969w, 908w, 871w. ¹H-NMR: 0.86 (*dm*, $J_{gem} = 11.5$, $J(2,10-exo) = J(5,10-exo) = 3.5$, $w_{1/2} \approx 2$, $H_{exo-C(10)}$); 1.45–1.8 (*m*, 2 $H-C(3)$, 2 $H-C(4)$, 2 $H-C(7)$, 2 $H-C(8)$); 1.84 (*dm*, $J_{gem} = 11.5$, $w_{1/2} \approx 6$, $H_{endo-C(10)}$); 1.98 (*s*, $exo-CH_3COO-C(9)$); 2.0–2.15 (*m*, $H-C(1)$, $H-C(2)$, $H-C(5)$, $H-C(6)$); 5.13 (*m*, $w_{1/2} \approx 4$, $H_{endo-C(9)}$). ¹³C-NMR: 21.49 (*q*, $exo-CH_3COO-C(9)$); 26.52 (*t*, $C(3)$, $C(4)$); 28.60 (*t*, $C(7)$, $C(8)$); 30.80 (*t*, $C(10)$); 39.37 (*d*, $C(2)$, $C(5)$); 43.41 (*d*, $C(1)$, $C(6)$); 79.23 (*d*, $C(9)$); 170.72 (*s*, $exo-CH_3COO-C(9)$). MS: 194 (1, M^+ , $C_{12}H_{18}O_2$), 152 (23), 134 (46), 119 (10), 106 (19), 95 (10), 93 (51), 92 (18), 91 (17), 81 (10), 80 (12), 79 (17), 67 (32), 66 (18), 43 (100), 41 (17), 28 (11).

b) From **25**. Hydrogenation (H_2 , 5% Pd/C) of 10 mg (0.05 mmol) of **25** in Et_2O for 2 h gave after workup and CC on 3 g silica gel in pentane/ Et_2O 19:1 9.5 mg (96%) of **28**.

REFERENCES

- [1] M. Bossi, C. Ganter, *Helv. Chim. Acta* **1987**, *70*, 1963.
- [2] H. W. Whitlock, Jr., M. Siefken, *J. Am. Chem. Soc.* **1968**, *90*, 4929.
- [3] E. M. Engler, M. Farcasiu, A. Sevin, J. M. Cense, P. v. R. Schleyer, *J. Am. Chem. Soc.* **1973**, *95*, 5769.
- [4] R. C. Fort, Jr., 'Adamantane. The Chemistry of Diamond Molecules', M. Dekker, Inc., New York, 1976.
- [5] W. P. Weber, in 'Reactivity and Structure Concepts in Organic Chemistry', 'Silicon Reagents for Organic Synthesis', Springer Verlag, Berlin, **1983**, Vol. 14, p. 273.
- [6] E. M. Engler, J. D. Andose, P. v. R. Schleyer, *J. Am. Chem. Soc.* **1973**, *95*, 8005.
- [7] C. Jaime, E. Osawa, *Tetrahedron* **1983**, *39*, 2769.
- [8] R. H. Boyd, S. N. Sanwal, S. Shary-Fehrany, D. McNally, *J. Phys. Chem.* **1971**, *75*, 1264.
- [9] B. Ernst, C. Ganter, *Helv. Chim. Acta* **1978**, *61*, 1107.
- [10] L. A. Paquette, G. Klein, C. W. Doecke, *J. Am. Chem. Soc.* **1978**, *100*, 1595.
- [11] L. A. Paquette, C. W. Doecke, G. Klein, *J. Am. Chem. Soc.* **1979**, *101*, 7599.
- [12] P. E. Eaton, D. R. Patterson, *J. Am. Chem. Soc.* **1978**, *100*, 2573.
- [13] A. Otterbach, H. Musso, *Angew. Chem.* **1987**, 588.
- [14] Y. Matoba, T. Kagayama, Y. Ishii, M. Ogawa, *Org. Magn. Reson.* **1981**, *17*, 144.
- [15] K. Nakagawa, S. Iwase, Y. Ishii, S. Hamanaka, M. Ogawa, *Bull. Chem. Soc. Jpn.* **1977**, *50*, 2391.

- [16] R. Herzsuh, H. Kühn, M. Mühlstädt, *J. Prakt. Chem.* **1983**, 325, 256.
- [17] I. Stopp, W. Engewald, H. Kühn, Th. Welsch, *J. Chromatogr.* **1978**, 147, 21.
- [18] P. v. R. Schleyer, M. M. Donaldson, *J. Am. Chem. Soc.* **1960**, 82, 4645.
- [19] N. Takaishi, H. Takahashi, O. Yamashita, Y. Inamoto, *J. Org. Chem.* **1986**, 51, 4862.
- [20] H. C. Brown, J. Rothberg, D. L. V. Jagt, *J. Org. Chem.* **1972**, 37, 4098.
- [21] J.-C. Fiaud, J.-Y. Legros, *J. Org. Chem.* **1987**, 52, 1907.
- [22] H. C. Brown, M. Periasamy, *J. Org. Chem.* **1981**, 46, 3166.
- [23] P. v. R. Schleyer, M. M. Donaldson, *J. Am. Chem. Soc.* **1956**, 78, 5702.
- [24] S. J. Cristoi, W. K. Seifert, S. B. Soloway, *J. Am. Chem. Soc.* **1960**, 82, 2351.
- [25] R. Schmid, Dissertation, Universität Zürich, 1978; R. Schmid, H. Schmid, *Helv. Chim. Acta* **1974**, 57, 1883.
- [26] H. E. Zimmerman, L. W. Linder, *J. Org. Chem.* **1985**, 50, 1637.
- [27] R. Pfund, C. Ganter, *Helv. Chim. Acta* **1979**, 62, 228.
- [28] A. M. Klester, C. Ganter, *Helv. Chim. Acta* **1983**, 66, 1200.
- [29] H.-R. Känel, C. Ganter, *Helv. Chim. Acta* **1985**, 68, 1226.